期刊文献+

顽固性高血压伴代谢综合征36例降压疗效观察 被引量:1

下载PDF
导出
摘要 目的探讨顽固性高血压伴代谢综合征的治疗效果。方法将每日口服缬沙坦胶囊80mg,吲达帕胺片2.5mg和硝苯地平控释片30mg治疗8周血压仍未达控制目标的顽固性高血压伴代谢综合征36例患者随机分为3组,各12例,每日A组加服吡格列酮片15mg和非诺贝特缓释片250mg,B组单加吡格列酮片15mg,C组单加非诺贝特缓释片250mg,加强治疗8周。治疗前后检测患者的血压、血清甘油三酯、空腹血糖水平及腰围的变化。结果加强治疗8周后,3组的血压、血清甘油三酯及空腹血糖水平较治疗前显著下降(P<0.01);A组的血压目标控制率的升高、空腹血糖和甘油三酯水平的下降比B组或C组有显著差异(P<0.01),但各组的腰围无显著变化(P>0.05)。结论吡格列酮联合非诺贝特能显著的改善缬沙坦、硝苯地平控释片和吲达帕胺对顽固性高血压伴代谢综合征的血压水平控制。
出处 《心脑血管病防治》 2011年第4期288-290,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献4

  • 1陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社.2009:704-706.
  • 2陈文彬,潘祥林.诊断学[M].第7版.北京:人民卫生出版社,2010:23.
  • 3陈灏珠,林果为.实用内科学[M].第13版.北京:人民卫生出版社,2009:2005-2011.
  • 4Matthew R. Weir. Providing End-Organ Protection with Renin-Angiotension System Inhibition : The Evidence So far[ J]. J Clin Hypertens, 2005,8 (2) :99 - 105.

共引文献613

同被引文献34

  • 1Marchi-Alves LM, Rigotti AR, Nogueira MS, et al. Metabolic syndrome components in arterial hypertension[J].Rev Esc En- ferm USP,2012,46(6) : 1348- 1353.
  • 2Koprowski P, Kostkiewicz M, Lesniak - Sobelga A. Echocardio graphic assessment of left atrial volume in asymptomatic ambu- latory patients with metabolic syndrome and/or arterial hyperten sion:is it parameter worth into considerate? [J].Przegl Lek, 2012,69(11) : 1199- 1204.
  • 3Morozova TE, Andrushchishina TB, Oshorova SD.Optimisation of arterial hypertension pharmacotherapy in patients with metabolic syndrome; potential of zofenopril[J].Russian Journal of Cardiol- ogy,2011(4) :63- 68.
  • 4Kinoshita S, Ryuzaki M, Sone M, et al. Effectiveness of using long - acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hyperten- sion monitoring by using telemedicine system (FWIYAMA study) [J].Clin Exp Hypertens,2014,36(7):508- 516.
  • 5Murakami K,Wada J,Ogawa D, et al .The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension, Abdominal fat Depot In- tervention Program of Okayama (ADIPO)[J].Diabetes & Vascu- lar Disease Research, 2013,10( 1 ) : 93 - 96.
  • 6Akyurek O,Akbal E, Gunes F, et al .Peroxisome proliferator- activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan [J].Archives of Medical Research,2014,45(2) :138 - 142.
  • 7Nedogoda SV, Chumachok EV, Ledyaeva AA, et al. Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension[J].Cardiovascular Therapy and Prevention, 2011,10(6) : 24 - 29.
  • 8Oleynikov V, Gusakovskaya L, Matrosova I, et al .Indicators of central pressure and rigidity during the long - term therapy of calcium antagonists in patients with metabolic syndrome and hy- pertension[J].Atherosclerosis, 2014,235(2) : E265.
  • 9Ueno N,Satou Y.The enhanced effect of atenolol on hyperten sion in metabolic syndrome[J].Metab Syndr Relat Disord, 2011,9(5):369- 373.
  • 10Krone W, Hanefeld M, Meyer HF, et al .Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome[J].J Hum Hypertens,2011,25(3) : 186 - 195.

引证文献1

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部